Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06234670
Other study ID # V1.0
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date January 25, 2024
Est. completion date January 1, 2025

Study information

Verified date January 2024
Source Tongji Hospital
Contact shixuan Wang, Phd
Phone 86-27-83663078
Email shixuanwang@tjh.tjmu.edu.cn
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

To research risk factors for recurrence of uterine fibroids and build a prediction model of recurrence of uterine fibroids to facilitate the early detection as well as the early intervention for patients who are prone to recur.


Description:

Uterine fibroids are the most common benign tumors of female reproductive organs during childbearing age. With the emphasis on fertility preservation and the pursuit of the physical integrity, about 46% of patients prefer the conservative surgery which preserves the uterus. However, the high recurrence rate of uterine fibroids after conservative surgery does cause formidable clinical problems. According to the literature, the recurrence rate is about 11.7% at one year after myomectomy and would increase steadily. At the eighth year of myomectomy, the recurrence rate is as high as 84.4%. During the long-term follow-up, about one-third of patients eventually require reoperation. Recurrence not only leads to the recurrence of fibroid-related symptoms such as anemia, abdominal and pelvic pain, frequent urination and urgency, abnormal stool, etc., but also increases the burden of economic and national medical insurance, besides, it even causes serious problems such as psychological disorders, infertility, adverse pregnancy outcomes and malignant transformation, which affecting physical and mental health as well as destroying family happiness and threatening national population security.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 3200
Est. completion date January 1, 2025
Est. primary completion date January 1, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria: 1. Age:18-50 years 2. Diagnosed with uterine fibroids (by ultrasound or pathology) 3. Accept myomectomy. 4. Complete clinical data. Exclusion Criteria: 1. Severe infectious disease 2. Previous history of malignant tumors 3. Incomplete clinical data. 4. Pregnant

Study Design


Related Conditions & MeSH terms


Intervention

Other:
No intervertion
This study is a retrospective observational study without intervention.

Locations

Country Name City State
China Shixuan Wang Wuhan None Selected

Sponsors (2)

Lead Sponsor Collaborator
Wenwen Wang Tongji Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary The performance of the prediction model for recurrence of uterine fibroids as assessed by AUC Complete the follow-up, and compare the actual recurrence population with the predicted recurrence population to judge the performance of the prediction model. Use the AUC (Area Under Curve) through study completion, about June.2025
Secondary Numbers of risk factors of recurrent uterine fibroids as certained by statistic analysis To identify the risk factors of recurrent uterine fibroids. We identify the risk factors through statistic analysis. Statistical significance proves to be the symbol of identifycation of risk factors. about June.2024
Secondary The recurrence rate of uterine fibroids yearly To calculate the recurrence rate of uterine fibroids yearly about Febrary.2024
Secondary The fertility rate after myomectomy To research the fertility rate after myomectomy and evaluate the impact of the surgery. about Febrary.2024
Secondary The quality of life after myomectomy will be assessed by UFS-QOL,(uterine fibroid symptom and health-related quality of life, UFS-QOL) To assess the quality of life after myomectomy, we use UFS-QOL.The UFS-QOL, the most popular self-administered instrument in assessing the whole spectrum of fibroid-related symptoms and health-related quality of life among patients with uterine fibroids, was designed in 2002s by James B et.al.
Consisting of eight symptom items and twenty-nine health-related quality of life (HRQL) items of six subscales (concern, activities, energy/mood, control, self-consciousness, and sexual functioning), UFS-QOL is scored with a 5-point scale which demonstrates the patient' state of past 3 months. The final score (range, 0-100) is transformed based on a specific formula. Usually, a higher symptom severity score means more severe symptoms while a higher HRQL score indicates more perfect health
through study completion, about June.2025
Secondary The degree of abdominal pain after myomectomy will be assessed by VAS(visual analogue scale, VAS) VAS is the most commonly used one-dimensional measure of pain intensity. The scale consists mainly of a 100 mm straight line with one end indicating "completely painless" and the other end indicating "the most severe pain imaginable" or "extremely painful", etc. Patients will be asked to mark the line at the appropriate location to represent the intensity of the pain they are experiencing at the time through study completion, about June.2025
Secondary The blood loss will be assessed by PBLAC (Pictorial Blood Loss Assessment Chart (PBLAC) The Pictorial Blood Loss Assessment Chart (PBLAC) proposed by Higham JM in 1990 is widely used internationally to evaluate menstrual flow. 1 Menstrual blood loss chart The menstrual blood loss chart is given different scores according to the different degrees of blood staining of each sanitary napkin: mild (1 point), the blood stained area < 1/3 of the whole sanitary napkin; Moderate (5 points): The blood stained area accounts for 1/3~3/5 of the whole sanitary napkin; Severe (20 points): The blood-stained area is basically the entire sanitary napkin. through study completion, about June.2025
See also
  Status Clinical Trial Phase
Completed NCT03545659 - Childhood Acute Lymphoblastic Leukaemia: Follow-Up
Completed NCT04838613 - Study of Diagnostic Performance of [18F]CTT1057 in BCR Phase 3
Recruiting NCT05233020 - Robotic Versus Hybrid Assisted Ventral Hernia Repair N/A
Recruiting NCT04539665 - Extended Mesenteric Excision in Ileocolic Resections for Crohn's Disease. N/A
Recruiting NCT04266600 - Extended Mesenteric Excision in Ileocolic Resections for Crohn's Disease N/A
Terminated NCT03257722 - Pembrolizumab + Idelalisib for Lung Cancer Study Phase 1/Phase 2
Completed NCT01141335 - Polypropylene Mesh Versus Polytetrafluoroethylene (PTFE) Mesh in Inguinal Hernia Repair Phase 4
Completed NCT00029185 - Study of Dehydrex in Patients With Corneal Erosion N/A
Completed NCT01351974 - Sentinel Node Biopsy in Breast Cancer Patients N/A
Not yet recruiting NCT06038422 - GTP Regimen in the Treatment of Refractory/Recurrent HLH Phase 3
Withdrawn NCT03162120 - Comparison of Effectiveness of Ranolazine Plus Metoprolol Combination vs. FlecainidE pluS Metoprolol Combination in ATrial Fibrillation Recurrences FOllowing PhaRmacological or Electrical CardioverSion of AtRial Fibrillation Phase 2/Phase 3
Recruiting NCT04159051 - Charité HT-Prostate N/A
Recruiting NCT02566928 - Patient-Centered Comparative Effectiveness Research (CER) Study of Home-based Interventions to Prevent CA-MRSA Infection Recurrence Phase 4
Completed NCT01989845 - Rivaroxaban for the Prevention of Venous Thromboembolism in Asian Patients With Cancer Phase 4
Recruiting NCT01229475 - Stepwise Approach Versus Linear Ablation in Patients With Recurrence of Persistent Atrial Fibrillation N/A
Completed NCT00944554 - Relapse Prevention With Varenicline Phase 4
Terminated NCT02247258 - Azathioprine in the Prevention of Ileal Crohn's Disease Postoperative Recurrence. Phase 2
Completed NCT03654209 - Post-resection Treatment of Large Colon Polyps N/A
Recruiting NCT05557474 - Development and Clinical Validation of Early-stage Lung Cancer Prognostic Kit
Active, not recruiting NCT03865537 - Cold Snare Endoscopic Mucosal Resection Trial N/A